The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1
Open Access
- 28 April 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4), e0232031
- https://doi.org/10.1371/journal.pone.0232031
Abstract
Patients with Neurofibromatosis type 1 (NF1) develop plexiform neurofibromas (PNF) and cutaneous neurofibromas. These tumors are a major cause of the patient’s morbidity and mortality. An influence of estrogen and progesterone on tumor growth has been suggested but reports on growth or malignant transformation of tumors during pregnancy remain anecdotal. The purpose of this study was to quantify growth of cutaneous and plexiform neurofibromas in NF1 patients during pregnancy, and to assess the onset of NF1 related symptoms. Retrospectively, 13 mothers with NF1 were included and compared to nullipara, nulligravida, age-matched women with NF1. All women received whole-body magnetic resonance imaging (MRI) before and after pregnancy or after a matched time period. Presence of plexiform and cutaneous neurofibromas was evaluated. PNF were subjected to semi-automated volumetry (MedX). The sum of the longest diameters (SLD) of representative cutaneous neurofibromas was determined for both groups. Clinical symptoms and subjective tumor growth were assessed. PNF were identified in 12/26 women (46.2%). Follow up showed neither new PNF nor a significant difference in growth rate (median tumor-growth/year: pregnant group—0.38% (IQR -1.1–5.4%) vs control group 3.59% (IQR -2.1–5.5%; P = 0.69). Malignant transformation of PNF was not observed. There was a significant growth of cutaneous neurofibromas in both groups (median SLD increase: pregnant group 17mm; P = 0.0026 / control group 12mm; P = 0.0004) The difference in increase of SLD was not significant (P = 0.48). Singular cutaneous neurofibromas in the pregnant group displayed high levels of tumor growth (>20%/year). NF1-associated symptoms and subjective tumor growth were not significantly increased in pregnant patients. Growth of plexiform and cutaneous neurofibromas in pregnant patients is not significantly different compared to non-pregnant patients. Cutaneous neurofibromas show a significant increase in growth over time in both, pregnant and non-pregnant patients and NF1 related clinical symptoms do not significantly aggravate during the course of pregnancy.Keywords
Funding Information
- Bundesverband Neurofibromatose e.V.
This publication has 32 references indexed in Scilit:
- Quantitative Assessment of Whole-Body Tumor Burden in Adult Patients with NeurofibromatosisPLOS ONE, 2012
- Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1Orphanet Journal of Rare Diseases, 2012
- Analysis of steroid hormone effects on xenografted human NF1 tumor schwann cellsCancer Biology & Therapy, 2010
- The role of steroid hormones in the NF1 phenotype: Focus on pregnancyAmerican Journal of Medical Genetics Part A, 2008
- In vitro studies of steroid hormones in neurofibromatosis 1 tumors and schwann cellsMolecular Carcinogenesis, 2007
- Neurofibromatosis type I and pregnancy: a fatal attraction? Development of malignant schwannoma during pregnancy in a patient with neurofibromatosis type IBJOG: An International Journal of Obstetrics and Gynaecology, 2003
- Review Article : Clinical Features and Pathobiology of Neurofibromatosis 1Journal of Child Neurology, 2002
- Maternal and perinatal complications in neurofibromatosis during pregnancyInternational Journal of Gynecology & Obstetrics, 1991
- A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling.Journal of Medical Genetics, 1989